Performed under clinical supervision with a pre-treatment doctor consultation
doi: 10.1172/jci.insight.133429 45 GaileyJ
This ruling may narrow the pool of viable claims, especially for individuals diagnosed based solely on clinical judgment
Laboratory monitoring should continue on whatever schedule your physician recommends
Patients were randomly assigned to orforglipron (12 mg or 36 mg) or semaglutide (7 mg or 14 mg) with a treatment period of 52 weeks, from 22 September 2022 to 22 August 2025, and drugs were administered orally once per day
2.3 Protein and amino-acid metabolism Lipid profile changes, such as increased triglycerides (TAG), low-density lipoprotein-cholesterol (LDL-C), and decreased high-density lipoprotein-cholesterol (HDL-C), are indicative of the metabolic dysregulation seen in type 2 diabetes and are strongly associated with insulin resistance and hyperglycemia (46, 60)